Press release
Transforming Growth Factor Beta (TGFb) Inhibitor Clinical Trials 2024: FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
TGFb Inhibitor Clinical Trials
(Albany, United States) As per DelveInsight's assessment, globally, Transforming Growth Factor Beta (TGFb) Inhibitor pipeline constitutes 90+ key companies continuously working towards developing 90+ Transforming Growth Factor Beta (TGFb) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Transforming Growth Factor Beta (TGFb) Inhibitor Market.
The Transforming Growth Factor Beta (TGFβ) Inhibitor Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, from the pre-clinical development phase to the marketed phase. This report includes detailed descriptions of the drugs, covering their mechanisms of action, clinical studies, NDA approvals (if any), and various product development activities. These activities encompass technology, collaborations, mergers and acquisitions, funding, designations, and other relevant product-related information.
Request for Sample Report @ https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Report:
• TGFb Inhibitor Companies across the globe are diligently working toward developing novel Transforming Growth Factor Beta (TGFb) Inhibitor treatment therapies with a considerable amount of success over the years.
• Transforming Growth Factor Beta (TGFb) Inhibitor companies working in the treatment market are Laekna Therapeutics, Sonnet Biotherapeutic, KaliVir Immunotherapeu tics, Isarna Therapeutics, Bristol-Myers Squibb, Acceleron Pharma Inc., Huabo Biopharm, Keros Therapeutics, Novartis Pharmaceutical, Merck Sharp & Dohme LLC, Jiangsu Hengrui Medicine, and others, are developing therapies for the Transforming Growth Factor Beta (TGFb) Inhibitor treatment
• Emerging Transforming Growth Factor Beta (TGFb) Inhibitor therapies in the different phases of clinical trials are- LAE-106, SON 3015, VET3-TGI, ASPH-1047, BMS 986416, MK-2225, HB002.1T, KER-050, NIS793, MK-7962, SHR 1701, and others are expected to have a significant impact on the Transforming Growth Factor Beta (TGFb) Inhibitor market in the coming years.
• SB-431542 and SB-505124, developed by GlaxoSmithKline, are notable inhibitors of TGF-β receptor kinase currently in the pre-clinical development stage. These inhibitors specifically hinder the phosphorylation of Smad2/3. In MG63 human osteosarcoma cells, the expression of c-myc, a gene typically suppressed by TGF-β in many cell types, was observed to increase. This implies that the upregulation of c-myc expression could potentially be the mechanism through which the inhibitory signals of TGF-β on cell growth are blocked in MG63 cells.
Transforming Growth Factor Beta (TGFb) Inhibitor Overview
Transforming Growth Factor Beta (TGFβ) inhibitors are an emerging class of therapeutic agents targeting the TGFβ signaling pathway, which plays a crucial role in cellular processes such as proliferation, differentiation, and immune regulation. Dysregulation of TGFβ signaling is implicated in various diseases, including cancer, fibrosis, and autoimmune disorders. By inhibiting TGFβ, these drugs aim to modulate the pathway's activity, thereby providing therapeutic benefits.
The development of TGFβ inhibitors is a rapidly advancing field with multiple compounds progressing through different stages of the pipeline, from pre-clinical research to clinical trials. These inhibitors are designed to block TGFβ ligands, receptors, or downstream signaling molecules, offering a targeted approach to disease treatment. Advances in molecular biology and drug design have facilitated the creation of more specific and potent TGFβ inhibitors, enhancing their efficacy and safety profiles.
Commercially, the TGFβ inhibitor market is expanding, driven by significant investments and collaborations between pharmaceutical companies and research institutions. Mergers and acquisitions are also common, aimed at accelerating the development and commercialization of these promising therapies. Robust funding from public and private sectors underscores the high therapeutic potential of TGFβ inhibitors. Overall, TGFβ inhibitors represent a promising avenue for treating a range of diseases, particularly where conventional therapies have been ineffective.
Get a Free Sample PDF Report to know more about Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Transforming Growth Factor Beta (TGFb) Inhibitor Drugs Under Different Phases of Clinical Development Include:
• LAE-106: Laekna Therapeutics
• SON 3015: Sonnet Biotherapeutic
• VET3-TGI: KaliVir Immunotherapeu tics
• ASPH-1047: Isarna Therapeutics
• BMS 986416: Bristol-Myers Squibb
• MK-2225: Acceleron Pharma Inc.
• HB002.1T: Huabo Biopharm
• KER-050: Keros Therapeutics
• NIS793: Novartis Pharmaceutical
• MK-7962: Merck Sharp & Dohme LLC
• SHR 1701: Jiangsu Hengrui Medicine
Transforming Growth Factor Beta (TGFb) Inhibitor Route of Administration
Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Transforming Growth Factor Beta (TGFb) Inhibitor Molecule Type
Transforming Growth Factor Beta (TGFb) Inhibitor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutics Assessment
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Product Type
• Transforming Growth Factor Beta (TGFb) Inhibitor By Stage and Product Type
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Route of Administration
• Transforming Growth Factor Beta (TGFb) Inhibitor By Stage and Route of Administration
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Molecule Type
• Transforming Growth Factor Beta (TGFb) Inhibitor by Stage and Molecule Type
DelveInsight's Transforming Growth Factor Beta (TGFb) Inhibitor Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Transforming Growth Factor Beta (TGFb) Inhibitor product details are provided in the report. Download the Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report to learn more about the emerging Transforming Growth Factor Beta (TGFb) Inhibitor therapies at: https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutics Market include:
Key companies developing therapies for Transforming Growth Factor Beta (TGFb) Inhibitor are - Oncotelic, Jiangsu Hengrui MedicineCo, Bristol-MyersSquibb, Rigel., BiogenIdec, Genentech, TilosTherapeutics, Eli Lilly and Company, and others.
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Analysis:
The Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Transforming Growth Factor Beta (TGFb) Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Transforming Growth Factor Beta (TGFb) Inhibitor Treatment.
• Transforming Growth Factor Beta (TGFb) Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Transforming Growth Factor Beta (TGFb) Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Transforming Growth Factor Beta (TGFb) Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Transforming Growth Factor Beta (TGFb) Inhibitor drugs and therapies- https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Market Drivers
• Increase in prevalence of Cancer, emerging as a highly promising, safe and effective anticancer agent are some of the important factors that are fueling the Transforming Growth Factor Beta (TGFb) Inhibitor Market.
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Market Barriers
• However, high cost associated with the treatment, limited understanding of the dual role of TGF-β as a tumor suppressor and tumor promoter in cancer and other factors are creating obstacles in the Transforming Growth Factor Beta (TGFb) Inhibitor Market growth.
Scope of Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key Transforming Growth Factor Beta (TGFb) Inhibitor Companies: Laekna Therapeutics, Sonnet Biotherapeutic, KaliVir Immunotherapeu tics, Isarna Therapeutics, Bristol-Myers Squibb, Acceleron Pharma Inc., Huabo Biopharm, Keros Therapeutics, Novartis Pharmaceutical, Merck Sharp & Dohme LLC, Jiangsu Hengrui Medicine, and others
• Key Transforming Growth Factor Beta (TGFb) Inhibitor Therapies: LAE-106, SON 3015, VET3-TGI, ASPH-1047, BMS 986416, MK-2225, HB002.1T, KER-050, NIS793, MK-7962, SHR 1701, and others
• Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutic Assessment: Transforming Growth Factor Beta (TGFb) Inhibitor current marketed and Transforming Growth Factor Beta (TGFb) Inhibitor emerging therapies
• Transforming Growth Factor Beta (TGFb) Inhibitor Market Dynamics: Transforming Growth Factor Beta (TGFb) Inhibitor market drivers and Transforming Growth Factor Beta (TGFb) Inhibitor market barriers
Request for Sample PDF Report for Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Transforming Growth Factor Beta (TGFb) Inhibitor Report Introduction
2. Transforming Growth Factor Beta (TGFb) Inhibitor Executive Summary
3. Transforming Growth Factor Beta (TGFb) Inhibitor Overview
4. Transforming Growth Factor Beta (TGFb) Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutics
6. Transforming Growth Factor Beta (TGFb) Inhibitor Late Stage Products (Phase II/III)
7. Transforming Growth Factor Beta (TGFb) Inhibitor Mid Stage Products (Phase II)
8. Transforming Growth Factor Beta (TGFb) Inhibitor Early Stage Products (Phase I)
9. Transforming Growth Factor Beta (TGFb) Inhibitor Preclinical Stage Products
10. Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutics Assessment
11. Transforming Growth Factor Beta (TGFb) Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Transforming Growth Factor Beta (TGFb) Inhibitor Key Companies
14. Transforming Growth Factor Beta (TGFb) Inhibitor Key Products
15. Transforming Growth Factor Beta (TGFb) Inhibitor Unmet Needs
16 . Transforming Growth Factor Beta (TGFb) Inhibitor Market Drivers and Barriers
17. Transforming Growth Factor Beta (TGFb) Inhibitor Future Perspectives and Conclusion
18. Transforming Growth Factor Beta (TGFb) Inhibitor Analyst Views
19. Appendix
20. About DelveInsight
Trending Report :
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-nec-epidemiology-forecast
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transforming Growth Factor Beta (TGFb) Inhibitor Clinical Trials 2024: FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3666657 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Inhibitor
Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
Historically, KRAS was considered an undruggable target…
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933
This latest report…
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as…
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide.
Super CORR…
